|

Liposomal ARA-C Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Depocyte

Pipeline

Phase 2: 1

Top Sponsors

  • New York Medical College1

Indications

  • Follicular Lymphoma, Grade III1
  • CD20+ Lymphoblastic Lymphoma1
  • Primary Mediastinal B-cell Lymphoma1
  • Burkitt Lymphoma1
  • Non-hodgkin Lymphoma1

Valhalla, New York1 trial

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

New York Medical College

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.